Beremagene geperpavec for epidermolysis bullosa dystrophica

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 May 2018: Trial started, NCT03536143
  2. 24 May 2018: Trial registered, NCT03536143

The trials

NCT03536143: A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

State
Completed
Phase
Phase 1 and Phase 2
People
12 taking part
Started
6 May 2018
Primary completion
1 Nov 2019
Arms
Topical beremagene geperpavec
Results
Posted on the registry
  1. 6 May 2018: Trial started
  2. 24 May 2018: Trial registered
  3. 1 Nov 2019: Trial completed
  4. 31 Jan 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as Topical beremagene geperpavec.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.